Fagan Associates, Inc. Gilead Sciences, Inc. Transaction History

Fagan Associates, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	BUY	$73.94 - $80.67 $56,933 - $62,115	770 Added 13.4%	6,515 $488,000
Q2 2023 Aug 08, 2023	BUY	$76.01 - $86.7 $45,606 - $52,020	600 Added 11.66%	5,745 $442,000
Q1 2023 May 03, 2023	BUY	$77.31 - $88.08 $129,803 - $147,886	1,679 Added 48.44%	5,145 $426,000
Q4 2022 Jan 25, 2023	BUY	$62.32 - $89.47 $216,001 - $310,103	3,466 New	3,466 $0
Q1 2018 May 08, 2018	SELL	$72.84 - $88.8 $2.52 Million - $3.07 Million	-34,594 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$71.15 - $83.52 $11,028 - $12,945	155 Added 0.45%	34,594 $2.48 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $98,358 - $116,581	1,364 Added 4.12%	34,439 $2.79 Million
Q2 2017 Aug 07, 2017	BUY	N/A	33,075	33,075 $2.34 Million

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Fagan Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Fagan Associates, Inc. with notifications on news.